April 25th 2024
A recent study revealed a significant increase in intrauterine device usage among reproductive-aged women in South Carolina following the implementation of the Choose Well initiative.
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
15th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 11, 2024
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
4th Annual International Congress on the Future of Women’s Health™
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More
Impact of serum estradiol decline before hCG-triggering on IVF outcomes
March 13th 2024A recent study delves into how serum estradiol decline preceding human chorionic gonadotropin administration affects in vitro fertilization outcomes, particularly among patients without oral contraceptive pretreatment, shedding light on the importance of monitoring during controlled ovarian hyperstimulation.
Read More
New guidelines revealed for no-cost FDA-approved contraceptives
January 23rd 2024The Biden-Harris administration, has released comprehensive guidance through Frequently Asked Questions to eliminate barriers to contraception, ensuring access to FDA-approved contraceptives at no cost, following President Biden's 2023 Executive Order.
Read More
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Smart Women’s Choice faces federal court order to halt unlawful contraceptive distribution
November 16th 2023The US District Court for the District of Arizona issued an order against Arizona-based company Smart Women’s Choice, Inc, following a complaint by the US Department of Justice, alleging the distribution of unapproved new drugs in violation of the Federal Food, Drug, and Cosmetic Act.
Read More
Treating heavy menstrual bleeding: Levonorgestrel system vs combined oral contraceptives
November 8th 2023In a recent study, patients who were treated for heavy menstrual bleeding with the levonorgestrel intrauterine system had similar changes in bleeding-related quality of life as those using combined oral contraceptives for treatment.
Read More
Enhancing contraceptive use among female smokers
October 26th 2023Women of reproductive age often use combined hormonal contraceptives, which are available orally, as a vaginal ring, or as a transdermal patch. However, CHCs are associated with increased risks of venous thromboembolism and myocardial infarction (MI).
Read More